Letrozole induces hepatotoxicity without causing oxidative stress: The protective effect of melatonin

Gynecological Endocrinology

Volumn 27, Issue 4, 2011, Pages 209-215

  Aydin, Mehmet ^a   Oktar, Süleyman ^a   Özkan, Orhan Veli ^a   Alçin, Ergül ^b   Öztürk, Oktay Hasan ^a   Nacar, Ahmet ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

Author keywords

estrogens; hepatotoxicity; Letrozole; melatonin; oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CATALASE; CREATININE; HIGH DENSITY LIPOPROTEIN; LETROZOLE; MALONALDEHYDE; MELATONIN; NITROGEN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; LIVER FUNCTION; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; AROMATASE INHIBITORS; DRUG-INDUCED LIVER INJURY; FEMALE; LIVER; MELATONIN; NITRILES; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES;

EID: 79952409335     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.488769     Document Type: Article

References (39)

1. Simpson ER, Mahendroo MS, Nichols JE, Bulun SE. Aromatase gene expression in adipose tissue: relationship to breast cancer. Int J Fertil Menopausal Stud 1994;39(Suppl 2):75-83.
2. Zapata E, Zubiaurre L, Bujanda L, Pierola A. Anastrozoleinduced hepatotoxicity. Eur J Gastroenterol Hepatol 2006;18: 1233-1234.
3. Femara1. Letrozole tablets, Vol. 1. East Hanover: Novartis Pharmaceuticals; 2001.
4. Green PS, Gordon K, Simpkins JW. Phenolic a ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol 1997;63:229-235. (Pubitemid 28137161)
5. Naftolin F, Perez J, Leranth CS, Redmond DE, Jr., Garcia- Segura LM. African green monkeys have sexually dimorphic and estrogen-sensitive hypothalamic neuronal membranes. Brain Res Bull 1990;25:575-579.
6. Liu Y, Shimizu I, Omoya T, Ito S, Gu XS, Zuo J. Protective effect of estradiol on hepatocytic oxidative damage. World J Gastroenterol 2002;8:363-366.
7. Reiter RJ, Korkmaz A, Paredes SD, Manchester LC, Tan DX. Melatonin reduces oxidative/nitrosative stress due to drugs, toxins, metals, and herbicides. Neuro Endocrinol Lett 2008;29:609-613.
8. Calvo JR, Reiter RJ, Garcia JJ, Ortiz GG, Tan DX, Karbownik M. Characterization of the protective effects of melatonin and related indoles against a-naphthylisothiocyanate-induced liver injury in rats. J Cell Biochem 2001;80:461-470. (Pubitemid 32127461)
9. Suzme R, Gurdol F, Deniz G, Ozden T: et al. Response in DNA ploidy of hepatocytes to tamoxifen and/or melatonin in vivo.Res Commun Mol Pathol Pharmacol 2001;109:275-286. (Pubitemid 36896758)
10. Karbownik M, Reiter RJ, Cabrera J, Garcia JJ. Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage. Mutat Res 2001;474:87-92. (Pubitemid 32184757)
11. Karbownik M, Reiter RJ, Burkhardt S, Gitto E, Tan DX, Lewinski A. Melatonin attenuates estradiol-induced oxidative damage to DNA: relevance for cancer prevention. Exp Biol Med (Maywood) 2001;226:707-712. (Pubitemid 32619611)
12. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990;186:407-421. (Pubitemid 20279982)
13. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497-500.
14. Aebi H. Methods of enzymatic analysis. In: Bergmeyer U, editor. New York: Academic Press; 1984.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
16. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable abts radical cation. Clin Biochem 2004;37: 277-285. (Pubitemid 38314881)
17. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-1111.
18. Kosecik M, Erel O, Sevinc E, Selek S. Increased oxidative stress in children exposed to passive smoking. Int J Cardiol 2005;100:61-64. (Pubitemid 40487937)
19. Pannen BH. New insights into the regulation of hepatic blood flow after ischemia and reperfusion. Anesth Analg 2002;94: 1448-1457. (Pubitemid 34556621)
20. Nakatani T, Inouye M, Mirochnitchenko O. Overexpression of antioxidant enzymes in transgenic mice decreases cellular ploidy during liver regeneration. Exp Cell Res 1997;236:137-146. (Pubitemid 27452357)
21. Glantzounis GK, Salacinski HJ, Yang W, Davidson BR, Seifalian AM. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review. Liver Transpl 2005;11:1031-1047. (Pubitemid 41341752)
22. Strehlow K, Rotter S, Wassmann S, Adam O, Grohe C, Laufs K, Bohm M, Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003;93:170-177. (Pubitemid 36919705)
23. Tschugguel W, Stonek F, Zhegu Z, Dietrich W, Schneeberger C, Stimpfl T, Waldhoer T, Vycudilik W, Huber JC. Estrogen increases endothelial carbon monoxide, heme oxygenase 2, and carbon monoxide-derived cgmp by a receptor-mediated system. J Clin Endocrinol Metab 2001;86:3833-3839. (Pubitemid 32755985)
24. Lee SY, Andoh T, Murphy DL, Chiueh CC. 17 b-estradiol activates ici 182,780-sensitive estrogen receptors and cyclic gmp-dependent thioredoxin expression for neuroprotection. Faseb J 2003;17:947-948.
25. Montano MM, Deng H, Liu M, Sun X, Singal R. Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications. Oncogene 2004;23:2442-2453. (Pubitemid 38520742)
26. Kiray M, Uysal N, Sonmez A, Acikgoz O, Gonenc S. Positive effects of deprenyl and estradiol on spatial memory and oxidant stress in aged female rat brains. Neurosci Lett 2004;354:225-228. (Pubitemid 38045350)
27. Lund SA, Murdoch J, Van Kirk EA, Murdoch WJ. Mitogenic and antioxidant mechanisms of estradiol action in preovulatory ovine follicles: relevance to luteal function. Biol Reprod 1999;61:388-392. (Pubitemid 29344753)
28. Tabassum H, Parvez S, Rehman H, Banerjee BD, Raisuddin S. Catechin as an antioxidant in liver mitochondrial toxicity: inhibition of tamoxifen-induced protein oxidation and lipid peroxidation. J Biochem Mol Toxicol 2007;21: 110-117. (Pubitemid 47080837)
29. Yuvaraj S, Premkumar VG, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Augmented antioxidant status in tamoxifen treated postmenopausal women with breast cancer on coadministration with coenzyme q10, niacin and riboflavin. Cancer Chemother Pharmacol 2008;61:933-941. (Pubitemid 351423120)
30. Tabassum H, Parvez S, Rehman H, Dev Banerjee B, Siemen D, Raisuddin S. Nephrotoxicity and its prevention by taurine in tamoxifen induced oxidative stress in mice. Hum Exp Toxicol 2007;26:509-518. (Pubitemid 47218493)
31. Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 2007;105(Suppl 1):7-17. (Pubitemid 47524797)
32. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006;20:1029-1039; discussion 1039-1040,1042,1048. (Pubitemid 46947932)
33. Kannel WB, Wilson PW. Comparison of risk profiles for cardiovascular events: implications for prevention. In: Schrier RW BJ, Ozau VJ, Fauci AS, Abboud FM, editors. Advances in internal medicine. St. Louis: Mosby-Year Book; 1997.43, pp 39-66.
34. Wojtacki J, Kruszewski WJ, Lesńiewski-Kmak K, S ́ liwiń ska M, Czyzewska K, Kruszewska E. Shortterm effects of anastrozole therapy on serum lipid profile in patients with breast cancer, previously treated with tamoxifen. Preliminary report. Nowotwory 2001;51:43-47. (Pubitemid 32435946)
35. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510-1513. (Pubitemid 32744681)
36. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (ncic ctg ma.17l). Ann Oncol 2005;16:707-715. (Pubitemid 40767090)
37. Kim SH, Lee SM. Cytoprotective effects of melatonin against necrosis and apoptosis induced by ischemia/ reperfusion injury in rat liver. J Pineal Res 2008;44:165-171.
38. Sulaiman AA, Al-Shawi NN, Jwaied AH, Mahmood DM, Hussain SA. Protective effect of melatonin against chlorpromazine- induced liver disease in rats. Saudi Med J 2006;27: 1477-1482. (Pubitemid 351833155)
39. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, et al. Phase iii study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 2003;21:2101-2109. (Pubitemid 46606358)